Compass Pathways, Transcend Therapeutics, and the Usona Institute have been named the first recipients of FDA National Priority Vouchers following...
The European Medicines Agency is taking steps to rethink how certain high-need medicines reach patients, with a new concept paper proposing a more flexible, evidence-based pathway...
A new clinical trial has found that psilocybin-assisted therapy may be better at helping people stop smoking than standard nicotine replacement treatment.
The U.S.
Clinical updates from Compass Pathways and Helus Pharma from last week marked a significant step forward in the psychedelics development landscape, with new data emerging from...
A new study investigates how so-called “self-transcendent” psychedelic states can trigger enduring changes in meaning-making, values, and perceptions of reality.
In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts, and incremental regulatory shifts began to...
A new study in The Journal of Neuroscience has shed light on how the psychedelic N,N-Dimethyltryptamine, or DMT, changes brain activity during its most intense psychological...
A newly published systematic review titled on psilocybin’s effects on obsessive‑compulsive behaviours provides an up-to-date synthesis of research into the compound’s potential for treating OCD and...
For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment.
